Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NTRA Stock Forecast 2026-2027
$274.39
Current Price
$39.30B
Market Cap
Buy 19
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to NTRA Price Targets
+13.0%
To High Target of $310.00
-1.6%
To Median Target of $270.00
-29.7%
To Low Target of $193.00
NTRA Price Momentum
-1.8%
1 Week Change
+23.1%
1 Month Change
+69.6%
1 Year Change
+19.8%
Year-to-Date Change
-4.7%
From 52W High of $288.04
+108.2%
From 52W Low of $131.81
📊 TOP ANALYST CALLS
Did NTRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Natera is one of their latest high-conviction picks.
Latest NTRA Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, NTRA has a bullish consensus with a median price target of $270.00 (ranging from $193.00 to $310.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $274.39, the median forecast implies a -1.6% downside. This outlook is supported by 19 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Eve Burstein at Bernstein, projecting a 13.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NTRA Analyst Ratings
19
Buy
3
Hold
0
Sell
NTRA Price Target Range
Low
$193.00
Average
$270.00
High
$310.00
Current: $274.39
Latest NTRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NTRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $300.00 |
| Jun 29, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $290.00 |
| Jun 26, 2026 | Bernstein | Eve Burstein | Outperform | Reinstates | $310.00 |
| Jun 24, 2026 | BTIG | Mark Massaro | Buy | Maintains | $275.00 |
| Jun 24, 2026 | Barclays | Luke Sergott | Overweight | Maintains | $260.00 |
| Jun 23, 2026 | BTIG | Mark Massaro | Buy | Maintains | $270.00 |
| Jun 11, 2026 | RBC Capital | Dan Leonard | Outperform | Reinstates | $275.00 |
| Jun 5, 2026 | Goldman Sachs | Neutral | Initiates | $N/A | |
| Jun 2, 2026 | Wolfe Research | Mike Polark | Outperform | Assumes | $260.00 |
| May 11, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 8, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| May 8, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| May 8, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 14, 2026 | William Blair | Outperform | Initiates | $N/A | |
| Mar 3, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Feb 27, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 27, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Feb 27, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Feb 27, 2026 | Baird | Outperform | Maintains | $N/A | |
| Jan 7, 2026 | Citigroup | Buy | Initiates | $N/A |
NATERA INC (Common Stock) – ticker 45E (NTRA) Competitors
The following stocks are similar to Natera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NATERA INC (Common Stock) – ticker 45E (NTRA) Financial Data
NATERA INC (Common Stock) – ticker 45E has a market capitalization of $39.30B with a P/E ratio of -180.4x. The company generates $2.50B in trailing twelve-month revenue with a -9.0% profit margin.
Revenue growth is +38.8% quarter-over-quarter, while maintaining an operating margin of -12.4% and return on equity of -15.0%.
Valuation Metrics
Market Cap
$39.30B
Enterprise Value
$38.45B
P/E Ratio
-180.4x
PEG Ratio
-9.0x
Price/Sales
15.7x
Growth & Margins
Revenue Growth (YoY)
+38.8%
Gross Margin
+64.7%
Operating Margin
-12.4%
Net Margin
-9.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+2.8%
Current Ratio
3.0x
Debt/Equity
13.5x
ROE
-15.0%
ROA
-9.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
NATERA INC (Common Stock) – ticker 45E (NTRA) Business Model
About NATERA INC (Common Stock) – ticker 45E
What They Do
Advanced genetic testing services for healthcare.
Business Model
Natera operates through a laboratory services model, providing advanced genetic testing primarily to obstetric, fertility, oncology, and specialty practices, as well as hospital systems. The company generates revenue by offering a range of non-invasive tests, including prenatal screenings, carrier screenings, and oncology testing, which are essential for clinical decision-making and personalized patient care.
Additional Information
Headquartered in Austin, Texas, Natera is positioned as a key player in the genetic diagnostics market, focusing on innovations that integrate seamlessly into clinical workflows. The company's diverse portfolio not only addresses reproductive health but also extends into oncology and organ health, highlighting its commitment to enhancing patient outcomes through genetic insights.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
4,424
CEO
Mr. Steven Leonard Chapman
Country
United States
IPO Year
2015
Website
www.natera.comNATERA INC (Common Stock) – ticker 45E (NTRA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
Jul 01, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Natera, Inc. (NASDAQ: NTRA) published new data in JAMA Oncology on its Signatera MRD test for colorectal liver metastases, also presented at the ESMO GI Congress.
Why It Matters
New data on Natera's Signatera MRD test could boost its market position and revenue potential, influencing stock performance and investor sentiment in precision medicine.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
A medical services stock is currently in a buy zone of a cup base, with the company's losses decreasing.
Why It Matters
The stock's positioning in a buy zone indicates potential for upward momentum, while decreasing losses suggest improving financial health, attracting bullish investor sentiment.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Natera's partnership with Aveta will integrate Signatera into a global Phase 3 trial for head and neck cancer, focusing on minimal residual disease (MRD) and treatment response.
Why It Matters
Natera's partnership and Phase 3 trial for Signatera could enhance its market position in oncology, potentially boosting revenue and attracting investor interest in future growth.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Natera, Inc. and Aveta Biomics have formed a strategic partnership for AVTA 30-01, a Phase 3 trial evaluating APG-157 for advanced head and neck cancer.
Why It Matters
Natera's partnership with Aveta Biomics for a Phase 3 trial may enhance its market position in precision medicine, impacting stock performance and investor confidence in future growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Natera and Aveta Biomics are partnering on a late-stage study for an experimental head and neck cancer therapy, focusing on improving patient treatment monitoring.
Why It Matters
The partnership between Natera and Aveta Biomics could enhance treatment monitoring for head and neck cancer, potentially leading to improved outcomes and market opportunities, impacting stock performance.
Source: Reuters
Market Sentiment:
Neutral
Quick Summary
Natera's stock rose after Japan approved its Signatera test for colon cancer detection.
Why It Matters
Natera's stock surge indicates market confidence following regulatory approval of its Signatera test, potentially boosting revenue and market share in cancer diagnostics.
Source: Investors Business Daily
Market Sentiment:
Positive
Frequently Asked Questions About NTRA Stock
What is NATERA INC (Common Stock) – ticker 45E's (NTRA) stock forecast for 2027?
Based on our analysis of 9 Wall Street analysts, NATERA INC (Common Stock) – ticker 45E (NTRA) has a median price target of $270.00. The highest price target is $310.00 and the lowest is $193.00.
Is NTRA stock a good investment in 2027?
According to current analyst ratings, NTRA has 19 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $274.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NTRA stock?
Wall Street analysts predict NTRA stock could reach $270.00 in the next 12 months. This represents a -1.6% decrease from the current price of $274.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NATERA INC (Common Stock) – ticker 45E's business model?
Natera operates through a laboratory services model, providing advanced genetic testing primarily to obstetric, fertility, oncology, and specialty practices, as well as hospital systems. The company generates revenue by offering a range of non-invasive tests, including prenatal screenings, carrier screenings, and oncology testing, which are essential for clinical decision-making and personalized patient care.
What is the highest forecasted price for NTRA NATERA INC (Common Stock) – ticker 45E?
The highest price target for NTRA is $310.00 from Eve Burstein at Bernstein, which represents a 13.0% increase from the current price of $274.39.
What is the lowest forecasted price for NTRA NATERA INC (Common Stock) – ticker 45E?
The lowest price target for NTRA is $193.00 from at , which represents a -29.7% decrease from the current price of $274.39.
What is the overall NTRA consensus from analysts for NATERA INC (Common Stock) – ticker 45E?
The overall analyst consensus for NTRA is bullish. Out of 9 Wall Street analysts, 19 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $270.00.
How accurate are NTRA stock price projections?
Stock price projections, including those for NATERA INC (Common Stock) – ticker 45E, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 9:22 AM UTC